ArticleJTO clinical and research reports2021

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis.

Alessandro Di Federico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.